IL318382A - Crystalline forms of an akr1c3 dependent kars inhibitor - Google Patents
Crystalline forms of an akr1c3 dependent kars inhibitorInfo
- Publication number
- IL318382A IL318382A IL318382A IL31838225A IL318382A IL 318382 A IL318382 A IL 318382A IL 318382 A IL318382 A IL 318382A IL 31838225 A IL31838225 A IL 31838225A IL 318382 A IL318382 A IL 318382A
- Authority
- IL
- Israel
- Prior art keywords
- kars
- inhibitor
- crystalline forms
- akr1c3
- dependent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compounds Of Unknown Constitution (AREA)
- Earth Drilling (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022107941 | 2022-07-26 | ||
| PCT/IB2023/057425 WO2024023666A1 (en) | 2022-07-26 | 2023-07-20 | Crystalline forms of an akr1c3 dependent kars inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL318382A true IL318382A (en) | 2025-03-01 |
Family
ID=87571498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL318382A IL318382A (en) | 2022-07-26 | 2023-07-20 | Crystalline forms of an akr1c3 dependent kars inhibitor |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250353847A1 (en) |
| EP (1) | EP4562010A1 (en) |
| JP (1) | JP2025524064A (en) |
| KR (1) | KR20250040692A (en) |
| CN (1) | CN119301125A (en) |
| AU (1) | AU2023314354A1 (en) |
| CA (1) | CA3259169A1 (en) |
| IL (1) | IL318382A (en) |
| MX (1) | MX2025000947A (en) |
| TW (1) | TW202409035A (en) |
| WO (1) | WO2024023666A1 (en) |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2779780A (en) | 1955-03-01 | 1957-01-29 | Du Pont | 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation |
| JP2002532415A (en) | 1998-12-16 | 2002-10-02 | ワーナー−ランバート・カンパニー | Treatment of arthritis with MEK inhibitors |
| AU7349801A (en) | 2000-07-19 | 2002-01-30 | Warner Lambert Co | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| WO2004007529A2 (en) | 2002-07-15 | 2004-01-22 | The Trustees Of Princeton University | Iap binding compounds |
| EP1478648B1 (en) | 2002-02-01 | 2014-04-30 | ARIAD Pharmaceuticals, Inc. | Phosphorus-containing compounds and uses thereof |
| CA2478065C (en) | 2002-03-08 | 2013-01-08 | Eisai Co. Ltd. | Macrocyclic compounds useful as pharmaceuticals |
| TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| GB0215823D0 (en) | 2002-07-09 | 2002-08-14 | Astrazeneca Ab | Quinazoline derivatives |
| US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
| BRPI0506883A (en) | 2004-01-16 | 2007-05-29 | Univ Michigan | conformational compressed smac mimetics and their uses |
| CN1933847A (en) | 2004-01-16 | 2007-03-21 | 密歇根大学董事会 | SMAC peptidomimetics and the uses thereof |
| US7345081B2 (en) | 2004-03-23 | 2008-03-18 | Genentech, Inc. | Azabicyclo-octane inhibitors of IAP |
| PL2253614T3 (en) | 2004-04-07 | 2013-03-29 | Novartis Ag | Inhibitors of IAP |
| KR100926203B1 (en) | 2004-07-02 | 2009-11-09 | 제넨테크, 인크. | Inhibitors of IAP |
| WO2006010118A2 (en) | 2004-07-09 | 2006-01-26 | The Regents Of The University Of Michigan | Conformationally constrained smac mimetics and the uses thereof |
| BRPI0513310A (en) | 2004-07-12 | 2008-05-06 | Idun Pharmaceuticals Inc | tetrapeptide analogs |
| JP5230865B2 (en) | 2004-07-15 | 2013-07-10 | テトラロジック ファーマシューティカルズ コーポレーション | IAP binding compound |
| MX2007007195A (en) | 2004-12-20 | 2007-10-08 | Genentech Inc | Pyrrolidine inhibitors of iap. |
| MX2008002114A (en) | 2005-07-21 | 2008-04-17 | Ardea Biosciences Inc | N-(arylamino)-sulfonamide inhibitors of mek. |
| NZ598890A (en) | 2007-04-30 | 2013-10-25 | Genentech Inc | Inhibitors of iap |
| BRPI0816769A2 (en) | 2007-09-12 | 2016-11-29 | Hoffmann La Roche | combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| WO2009055730A1 (en) | 2007-10-25 | 2009-04-30 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| UY38806A (en) | 2019-08-01 | 2021-02-26 | Novartis Ag | AKR1C3-DEPENDENT KARS TRICYCLIC INHIBITOR COMPOUNDS, COMPOSITIONS AND THEIR USES |
-
2023
- 2023-07-20 JP JP2025504088A patent/JP2025524064A/en active Pending
- 2023-07-20 US US18/871,590 patent/US20250353847A1/en active Pending
- 2023-07-20 EP EP23754402.8A patent/EP4562010A1/en active Pending
- 2023-07-20 AU AU2023314354A patent/AU2023314354A1/en active Pending
- 2023-07-20 CN CN202380043347.1A patent/CN119301125A/en active Pending
- 2023-07-20 KR KR1020257005399A patent/KR20250040692A/en active Pending
- 2023-07-20 CA CA3259169A patent/CA3259169A1/en active Pending
- 2023-07-20 IL IL318382A patent/IL318382A/en unknown
- 2023-07-20 WO PCT/IB2023/057425 patent/WO2024023666A1/en not_active Ceased
- 2023-07-24 TW TW112127478A patent/TW202409035A/en unknown
-
2025
- 2025-01-23 MX MX2025000947A patent/MX2025000947A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2025000947A (en) | 2025-03-07 |
| CN119301125A (en) | 2025-01-10 |
| CA3259169A1 (en) | 2024-02-01 |
| AU2023314354A1 (en) | 2024-11-21 |
| US20250353847A1 (en) | 2025-11-20 |
| KR20250040692A (en) | 2025-03-24 |
| EP4562010A1 (en) | 2025-06-04 |
| WO2024023666A1 (en) | 2024-02-01 |
| TW202409035A (en) | 2024-03-01 |
| JP2025524064A (en) | 2025-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285493A (en) | Crystalline forms of an rsk inhibitor | |
| IL316075A (en) | Crystalline form of lanifibranor | |
| SI4058453T1 (en) | Improved synthesis of kras g12c inhibitor compound | |
| ZA202106766B (en) | Compounds as inhibitors of macrophage migration inhibitory factor | |
| IL287792A (en) | Tricyclic akr1c3 dependent kars inhibitors | |
| IL314049A (en) | Parp7 inhibitors | |
| EP4582427A4 (en) | Usp1 inhibitor | |
| EP3870181A4 (en) | CRYSTALLINE FORMS OF AN ALK2 INHIBITOR | |
| EP3923948A4 (en) | Crystalline forms of a jak2 inhibitor | |
| IL320747A (en) | Piperidine derivatives as mettl3 inhibitors | |
| IL317006A (en) | Prodrugs of stat3 inhibitors | |
| EP3996707A4 (en) | CRYSTALLINE FORMS OF PLASMA KALLICREIN INHIBITORS | |
| GB202307924D0 (en) | Inhibitor compounds | |
| GB202300881D0 (en) | Inhibitor compounds | |
| HK40120423A (en) | Crystalline forms of an akr1c3 dependent kars inhibitor | |
| IL326113A (en) | Methods of using factor B inhibitors | |
| IL319472A (en) | Physical forms of an inhibitor of prc2 | |
| EP3927704A4 (en) | Crystalline forms of a jak2 inhibitor | |
| EP4479051A4 (en) | CRYSTALLINE (+)-TETRABENAZINE | |
| GB202014196D0 (en) | Crystalline form III of tetraacetylethylenediamine | |
| SMT202600195T1 (en) | Crystalline forms of evenamide | |
| MX2025000947A (en) | Crystalline forms of an akr1c3 dependent kars inhibitor | |
| CA3287070A1 (en) | Crystalline forms of an azetidine parp1 inhibitor | |
| CA3288524A1 (en) | Crystalline forms of evenamide | |
| CA3258544A1 (en) | Methods of tricyclic akr1c3 dependent kars inhibitor dosing |